Hallucinogen Use Disorder: Symptoms, Causes, Diagnosis, and Treatment

Hallucinogen use disorder is a substance use disorder characterized by a problematic pattern of hallucinogen use that leads to clinically significant impairment or distress. Hallucinogens are a diverse class of psychoactive substances that profoundly alter perception, thought, and mood — often producing vivid visual, auditory, or tactile experiences that are not grounded in external reality.

The DSM-5-TR recognizes two distinct categories within this diagnosis:

• Phencyclidine use disorder — involving PCP (phencyclidine) and related substances such as ketamine
• Other hallucinogen use disorder — involving substances such as LSD (lysergic acid diethylamide), psilocybin ("magic mushrooms"), mescaline (peyote), DMT (dimethyltryptamine), MDMA (3,4-methylenedioxymethamphetamine), and various synthetic hallucinogens

This distinction matters clinically because phencyclidine and related arylcyclohexylamines produce a different pharmacological and behavioral profile than classic serotonergic hallucinogens like LSD and psilocybin. PCP, for example, acts primarily on NMDA glutamate receptors and is associated with more severe behavioral disturbances, including aggression and psychotic-like states.

How common is it? According to the DSM-5-TR and data from the National Institute on Mental Health (NIMH), hallucinogen use disorder is relatively uncommon compared to alcohol or cannabis use disorders. The 12-month prevalence of other hallucinogen use disorder is estimated at approximately 0.1% among adults aged 12 and older in the United States. Phencyclidine use disorder is even rarer. However, overall hallucinogen use has been increasing, particularly among young adults aged 18–25, with national survey data showing a significant rise in past-year hallucinogen use in recent years. Notably, most people who use hallucinogens do not develop a diagnosable use disorder, but a meaningful subset does experience persistent, problematic use patterns.

The DSM-5-TR defines hallucinogen use disorder through a set of 11 criteria that broadly fall into four clusters: impaired control, social impairment, risky use, and pharmacological indicators. A diagnosis requires at least two of these criteria occurring within a 12-month period.

Impaired control:

• Using hallucinogens in larger amounts or over a longer period than intended
• Persistent desire or unsuccessful attempts to cut down or stop use
• Spending excessive time obtaining, using, or recovering from hallucinogen effects
• Craving — a strong desire or urge to use hallucinogens

Social impairment:

• Recurrent hallucinogen use resulting in failure to fulfill major obligations at work, school, or home
• Continued use despite persistent or recurrent social or interpersonal problems caused or worsened by the substance
• Giving up or reducing important social, occupational, or recreational activities because of hallucinogen use

Risky use:

• Recurrent hallucinogen use in physically hazardous situations (e.g., driving while intoxicated)
• Continued use despite knowledge of a persistent physical or psychological problem that is likely caused or worsened by the substance

Pharmacological indicators:

• Tolerance — needing markedly increased amounts to achieve the desired effect, or experiencing a diminished effect with continued use of the same amount. Classic hallucinogens like LSD produce rapid tolerance (tachyphylaxis), often within days of repeated use, which typically reverses quickly with abstinence.

Notably, withdrawal is not an established criterion for other hallucinogen use disorder in the DSM-5-TR, meaning the diagnosis can be made based on 10 rather than 11 possible criteria. PCP, however, does have an associated withdrawal syndrome. This pharmacological distinction is one reason many people underestimate the potential for problematic hallucinogen use — the absence of a classic physical withdrawal does not mean the pattern of use is not harmful or disordered.

Behavioral warning signs that friends, family, or the individual might notice include:

• Increasing preoccupation with obtaining or using hallucinogens
• Social withdrawal or a shift toward peer groups centered on drug use
• Declining academic or professional performance
• Unusual perceptual experiences or disorientation persisting beyond the period of intoxication
• Episodes of intense fear, paranoia, or panic during or after use (colloquially called "bad trips")
• Persistent visual disturbances after use has stopped, which may indicate hallucinogen persisting perception disorder (HPPD)

Like all substance use disorders, hallucinogen use disorder arises from a complex interaction of biological, psychological, and social factors. No single cause is sufficient — rather, multiple vulnerabilities converge to increase risk.

Biological and genetic factors:

• Genetic predisposition: Research on the heritability of hallucinogen use disorder specifically is limited, but the broader substance use disorder literature consistently shows that genetic factors account for approximately 40–60% of vulnerability to addictive disorders. Family history of any substance use disorder increases risk.
• Neurobiological mechanisms: Classic hallucinogens primarily act as agonists at serotonin 5-HT2A receptors, producing their characteristic perceptual effects. PCP and ketamine act as NMDA receptor antagonists. Individual differences in these receptor systems may influence susceptibility to both the reinforcing effects and the adverse consequences of these substances.
• Pre-existing mental health conditions: Individuals with mood disorders, anxiety disorders, or psychotic spectrum conditions are at elevated risk. Hallucinogen use can unmask or exacerbate latent psychotic vulnerabilities, and people with underlying psychological distress may use hallucinogens as a maladaptive coping strategy.

Psychological factors:

• Sensation seeking and novelty seeking: High scores on personality traits related to openness to experience and sensation seeking are consistently associated with hallucinogen use initiation.
• Early adverse experiences: Childhood trauma, neglect, and adverse childhood experiences (ACEs) are well-established risk factors for substance use disorders broadly.
• Cognitive beliefs about hallucinogens: A perception that hallucinogens are "safe" or "non-addictive" — a belief that is widespread in popular culture — can lower perceived risk and promote continued use despite emerging problems.

Social and environmental factors:

• Peer influence: Social networks in which hallucinogen use is normalized or encouraged are a strong predictor of initiation and continued use, particularly among adolescents and young adults.
• Cultural and subcultural context: Hallucinogen use is embedded in certain music, festival, and spiritual communities, which can create social reinforcement for use.
• Age of first use: Earlier initiation of substance use is consistently associated with higher risk of developing a use disorder.
• Availability and access: The growing availability of novel synthetic hallucinogens (such as NBOMe compounds and various tryptamine analogs) through online markets has expanded access, particularly among younger populations.

It is worth emphasizing that most people who try hallucinogens do not develop a use disorder. The transition from recreational use to disordered use typically involves an escalating pattern in which use becomes a primary coping mechanism, progressively interferes with functioning, and continues despite negative consequences.

Diagnosis of hallucinogen use disorder is made by a qualified clinician — typically a psychiatrist, psychologist, or addiction medicine specialist — based on a comprehensive clinical evaluation guided by DSM-5-TR criteria.

The diagnostic process typically includes:

• Clinical interview: A thorough history of substance use, including types of hallucinogens used, frequency, quantity, duration of use, and the context in which use occurs. The clinician explores the specific DSM-5-TR criteria to determine whether the pattern meets the diagnostic threshold of at least two criteria within a 12-month period.
• Assessment of severity: The DSM-5-TR specifies severity based on the number of criteria met: mild (2–3 criteria), moderate (4–5 criteria), or severe (6 or more criteria).
• Psychiatric evaluation: Because hallucinogen use is frequently associated with co-occurring mental health conditions, a comprehensive psychiatric assessment is essential. The clinician must determine whether symptoms such as psychosis, depression, or anxiety are substance-induced or reflect an independent psychiatric disorder — a distinction with significant treatment implications.
• Medical evaluation: Physical examination and laboratory testing help assess overall health, identify medical complications, and rule out other substances that may be contributing to the clinical picture. Standard urine drug screens detect PCP but do not reliably detect many classic hallucinogens like LSD or psilocybin, which are metabolized rapidly and at very low doses.
• Collateral information: When available, information from family members, partners, or other providers adds important context to the assessment.
• Standardized screening instruments: Tools such as the ASSIST (Alcohol, Smoking and Substance Involvement Screening Test) or the DAST (Drug Abuse Screening Test) can support but not replace clinical judgment.

Important differential diagnoses include:

• Hallucinogen intoxication — acute effects of recent use that do not meet the broader pattern required for a use disorder diagnosis
• Hallucinogen persisting perception disorder (HPPD) — persistent re-experiencing of perceptual disturbances ("flashbacks") after hallucinogen use has ceased, which is a separate diagnostic entity
• Substance/medication-induced psychotic disorder — psychotic symptoms that emerge during or shortly after hallucinogen use
• Primary psychotic disorders — such as schizophrenia or brief psychotic disorder, which must be carefully distinguished from substance-induced states

Self-diagnosis is unreliable and potentially harmful. If patterns of hallucinogen use are causing distress or functional impairment, a professional evaluation is the appropriate next step.

There are currently no FDA-approved medications specifically for hallucinogen use disorder — a notable gap compared to treatments available for opioid, alcohol, and nicotine use disorders. Treatment is primarily psychosocial and behavioral, tailored to the individual's pattern of use, co-occurring conditions, and psychosocial circumstances.

Psychotherapy and behavioral interventions:

• Cognitive-behavioral therapy (CBT): CBT is the most widely studied psychotherapeutic approach for substance use disorders and is considered a first-line treatment. It helps individuals identify and modify the thoughts, beliefs, and behavioral patterns that maintain substance use. For hallucinogen use disorder, CBT addresses distorted beliefs about the safety or necessity of use, builds coping skills for triggers and cravings, and develops relapse prevention strategies.
• Motivational interviewing (MI) and motivational enhancement therapy (MET): These approaches are particularly valuable when individuals are ambivalent about changing their substance use. MI uses a collaborative, non-confrontational style to help people explore their own motivations for change — an approach well-suited to hallucinogen users who may not perceive their use as problematic.
• Contingency management (CM): This behavioral approach provides tangible incentives for verified abstinence and treatment engagement. While more extensively studied in stimulant and opioid use disorders, the principles apply to hallucinogen use disorder as well.
• 12-step facilitation and mutual support groups: Participation in peer support groups such as Narcotics Anonymous (NA) can provide ongoing social support, structure, and accountability during recovery.
• Family therapy: Especially relevant for adolescents and young adults, family-based interventions address the relational dynamics that may contribute to or maintain problematic use.

Pharmacological management:

• While no medications target hallucinogen use disorder directly, pharmacotherapy matters in managing co-occurring conditions — such as depression, anxiety, or PTSD — that frequently accompany the disorder and, if untreated, increase relapse risk.
• For acute hallucinogen intoxication with severe agitation or psychosis, benzodiazepines are the first-line pharmacological intervention in emergency settings. Antipsychotics may be used cautiously, though they are generally avoided in classic hallucinogen intoxication unless necessary, because of potential complications.
• For PCP intoxication, which can present with severe agitation, violence, or medical instability, management is more intensive and may require sedation, supportive medical care, and close monitoring.

Levels of care:

• Outpatient treatment: Appropriate for mild to moderate cases, involving regular therapy sessions and monitoring.
• Intensive outpatient programs (IOP): Provide more structured support while allowing the individual to maintain daily responsibilities.
• Residential or inpatient treatment: Indicated for severe cases, particularly when there are significant co-occurring psychiatric conditions, unstable living situations, or failed outpatient attempts.

Treatment planning should be individualized, addressing the full scope of the person's needs rather than focusing solely on substance use.

The prognosis for hallucinogen use disorder is generally considered favorable relative to many other substance use disorders, though outcomes vary significantly depending on severity, duration of use, co-occurring conditions, and the quality of treatment and support.

Factors associated with better outcomes:

• Shorter duration and lower severity of use
• Strong social support and stable living environment
• Absence of co-occurring severe mental illness
• Early engagement in treatment
• High motivation for change
• No concurrent polysubstance use

Factors associated with poorer outcomes:

• Polysubstance use — many individuals who use hallucinogens problematically also use other substances such as cannabis, alcohol, or stimulants, which complicates treatment and recovery
• Co-occurring psychotic spectrum disorders or severe mood disorders
• Early age of onset
• Limited access to treatment or social support
• Continued exposure to environments where hallucinogen use is normalized

Potential long-term complications:

• Hallucinogen persisting perception disorder (HPPD): A subset of individuals develops persistent visual disturbances — such as trailing images, halos, geometric patterns, or intensified colors — that can last months or years after cessation. HPPD can be distressing and functionally impairing, and treatment options are limited, though some individuals respond to certain medications under psychiatric supervision.
• Substance-induced psychotic disorder: In vulnerable individuals, hallucinogen use can trigger prolonged psychotic episodes that persist well beyond the period of intoxication.
• Persistent anxiety or depressive symptoms: Particularly following intensely distressing hallucinogenic experiences.

Recovery is best understood as an ongoing process rather than a discrete event. Many individuals achieve sustained remission, particularly with adequate treatment and support. The DSM-5-TR allows clinicians to specify whether the disorder is in early remission (3–12 months without meeting criteria, except craving) or sustained remission (12 or more months without meeting criteria, except craving).

Hallucinogen use disorder frequently occurs alongside or shares features with several other psychiatric conditions. Understanding these relationships is important for accurate diagnosis and comprehensive treatment.

• Other substance use disorders: Polysubstance use is common. Individuals with hallucinogen use disorder frequently also use cannabis, alcohol, MDMA, or stimulants. Each co-occurring substance use disorder must be identified and addressed in treatment.
• Hallucinogen persisting perception disorder (HPPD): A distinct condition in which perceptual disturbances experienced during hallucinogen intoxication recur or persist after use has stopped. HPPD is not a use disorder itself but is a direct consequence of hallucinogen exposure.
• Substance/medication-induced psychotic disorder: Hallucinogens — particularly PCP, high-dose LSD, and synthetic cannabinoids with hallucinogenic properties — can induce psychotic states that require differentiation from primary psychotic disorders like schizophrenia.
• Schizophrenia spectrum disorders: There is a well-documented association between hallucinogen use and the onset or exacerbation of psychotic disorders in genetically vulnerable individuals. Hallucinogen use does not cause schizophrenia, but it can accelerate its onset in those with pre-existing vulnerability.
• Depressive disorders and anxiety disorders: Both are common co-occurring conditions. The relationship is bidirectional — individuals may use hallucinogens to cope with depression or anxiety, while hallucinogen use can worsen or trigger these conditions.
• Post-traumatic stress disorder (PTSD): Some individuals with PTSD use hallucinogens as an attempt at self-medication. This is distinct from the emerging clinical research investigating controlled, supervised use of MDMA or psilocybin as therapeutic interventions — research that is conducted under strict protocols entirely different from recreational use.
• Personality disorders: Particularly borderline personality disorder and antisocial personality disorder, which are associated with elevated rates of substance use disorders in general, including hallucinogen use disorder.

Seeking professional evaluation is appropriate whenever hallucinogen use begins to interfere with daily life, relationships, health, or psychological well-being. Because hallucinogens are widely perceived as low-risk substances, many people delay seeking help — or do not recognize that their pattern of use has become problematic.

Seek help promptly if you or someone you know experiences:

• Repeated use of hallucinogens despite a desire to cut down or stop
• Declining performance at work, school, or in personal responsibilities related to hallucinogen use
• Relationship conflicts caused or worsened by hallucinogen use
• Using hallucinogens in physically dangerous situations (e.g., while driving or in unfamiliar environments)
• Persistent psychological distress following hallucinogen use, including anxiety, paranoia, or depressive symptoms
• Persistent visual disturbances or perceptual changes that continue after the substance has worn off (possible HPPD)
• Episodes of psychosis, severe confusion, or disorientation during or after use
• Increasing preoccupation with hallucinogen use as a central activity in daily life

Seek emergency medical attention immediately if someone:

• Exhibits severe agitation, aggression, or self-harm during hallucinogen intoxication
• Experiences a psychotic episode with loss of contact with reality
• Shows signs of medical emergency such as hyperthermia, seizures, or cardiovascular distress — particularly with PCP, synthetic hallucinogens, or unknown substances
• Expresses suicidal thoughts or intentions

Where to start:

• A primary care physician can conduct an initial assessment and provide referrals
• Psychiatrists and addiction medicine specialists are equipped to diagnose and treat hallucinogen use disorder
• The SAMHSA National Helpline (1-800-662-4357) provides free, confidential referrals 24 hours a day, 7 days a week
• The 988 Suicide & Crisis Lifeline (call or text 988) is available for anyone in emotional distress or crisis

There is no minimum threshold of severity required to seek help. If hallucinogen use is causing concern — whether your own or someone else's — that concern itself is sufficient reason to consult a professional.